Post-treatment with nicotinamide (vitamin B3) reduces the infarct volume following permanent focal cerebral ischemia in female Sprague–Dawley and Wistar rats

doi:10.1016/S0304-3940(00)00854-5

Neuroscience Letters

Volume 281, Issues 2–3, 10 March 2000, Pages 111-114

https://doi.org/10.1016/S0304-3940(00)00854-5 Get rights and content

Abstract

Delayed treatment with nicotinamide (NAm) protects male rats against cerebral ischemia. Since the preponderant use of male animals in stroke research may produce results not applicable to female stroke patients due to gender-related differences, we examined whether delayed NAm treatment could protect female rats against focal cerebral ischemia using a model of permanent middle cerebral artery occlusion (MCAo). NAm (500 mg/kg) given intravenously, 2 h after MCAo, significantly reduced the infarct volume of female Sprague–Dawley (55%, P<0.05) and Wistar rats (60%, P<0.05) rats when compared with saline-injected controls. These studies confirm that NAm is neuroprotective specifically at the dose of 500 mg/kg in rats. The novel findings are that this neuroprotection occurs in female, as well as male rats, and that the neuroprotection observed is more robust when administered as an intravenous bolus compared with intraperitoneal administration.

Section snippets

Acknowledgements

K.I.M. is a Minority Awardee of the American Heart Association and C.S.O. was supported by NIH grant #NS 01732.

References (20)

I.A. Ayoub et al.
Nicotinamide reduces infarction up to two hours after the onset of permanent focal cerebral ischemia in Wistar rats
Neurosci. Lett.
(1999)
M.R.L. Stratford
Pharmacokinetics of nicotinamide and its effect on blood pressure, pulse and body temperature in normal human volunteers
Radiother. Oncol.
(1992)
K. Takahashi et al.
Post-treatment with an inhibitor of poly(ADP-ribose) polymerase attenuates cerebral damage in focal ischemia
Brain Res.
(1999)
Y.Q. Zhang et al.
Effects of gender and estradiol treatment on focal brain ischemia
Brain Res.
(1998)
N.J. Alkayed et al.
Gender-linked brain injury in experimental stroke
Stroke
(1998)
I.A. Ayoub et al.
Delayed treatment with nicotinamide improves neurologic outcome and reduces infarction volume in transient focal cerebral ischemia in rats
Soc. Neurosci. Abstr.
(1999)
M.F. Beal et al.
Coenzyme Q₁₀ and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate
Ann. Neurol.
(1994)
R.C. Becker et al.
Thrombolysis in myocardial infarction investigators
Comparison of clinical outcomes for women and men after acute myocardial infarction. Ann. Intern. Med.
(1994)
J.B. Bederson et al.
Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke
(1986)
L. Belayev et al.
Middle cerebral artery occlusion in the rat by intraluminal suture
Neurological and pathological evaluation of an improved model, Stroke
(1996)

There are more references available in the full text version of this article.

Cited by (71)

Antioxidant therapies in traumatic brain injury
2022, Neurochemistry International
Oxidative stress plays a crucial role in traumatic brain injury (TBI) pathogenesis. Reactive oxygen species (ROS) and reactive nitrogen species (RNS) formed in excess after TBI synergistically contribute to secondary brain damage together with lipid peroxidation products (reactive aldehydes) and inflammatory mediators. Furthermore, oxidative stress, endoplasmic reticulum stress and inflammation potentiate each other. Following TBI, excessive oxidative stress overloads the endogenous cellular antioxidant system leading to cell death. To combat oxidative stress, several antioxidant therapies were tested in preclinical animal models of TBI. These include free radical scavengers, activators of antioxidant systems, Inhibitors of free radical generating enzymes and antioxidant enzymes. Many of these therapies showed promising outcomes including reduced edema, blood-brain barrier (BBB) protection, smaller contusion volume, and less inflammation. In addition, many antioxidant therapies also promoted better sensory, motor, and cognitive functional recovery after TBI. Overall, preventing oxidative stress is a viable therapeutic option to minimize the secondary damage and to improve the quality of life after TBI.
Inhibition effect of nicotinamide (vitamin B<inf>3</inf>) and reduced glutathione (GSH) peptide on angiotensin-converting enzyme activity purified from sheep kidney
2021, International Journal of Biological Macromolecules
Angiotensin-converting enzyme (ACE, EC 3.4.15.1) plays a significant role in blood pressure regulation and inhibition of this enzyme is one of the significant drug targets for the treatment of hypertension. In this work, ACE was purified from sheep kidneys with the affinity chromatography method in one step. The purity and molecular weight of ACE were designated using the SDS-PAGE method and observed two bands at around 60 kDa and 70 kDa on the gel. The effects of nicotinamide (vitamin B₃) and reduced glutathione (GSH) peptide on purified ACE were researched. Nicotinamide and GSH peptide on purified ACE showed an inhibition effect. IC₅₀ values for nicotinamide and GSH were calculated as 14.3 μM and 7.3 μM, respectively. Type of inhibition and K_i values for nicotinamide and GSH from the Lineweaver-Burk graph were determined. The type of inhibition for nicotinamide and GSH was determined as non-competitive inhibition. K_i value was calculated as 15.4 μM for nicotinamide and 6.7 μM for GSH. Also, GSH peptide showed higher inhibitory activity on ACE activity than nicotinamide. In this study, it was concluded that nicotinamide and GSH peptide compounds, which show an inhibition effect on ACE activity, may have both protective and therapeutic effects against hypertension.
Pharmacokinetics of the SABRE agent 4,6-d <inf>2</inf> -nicotinamide and also nicotinamide in rats following oral and intravenous administration
2019, European Journal of Pharmaceutical Sciences
Citation Excerpt :
The pharmacokinetics of NA are known to be dependent on dose, species, sex and route of administration. Safe doses in rats have previously been characterized: 750 mg/kg for subcutaneous injection and 1000 mg/kg for IP injection (Ayouba et al., 1999) Furthermore, intravenous (IV) doses of 750 mg/kg in rat models of stroke (Sakakibara et al., 2000) have been used. An in vitro cytotoxicity study demonstrated that it is possible to create a biocompatible SABRE bolus of d2-NA and that deuteration of NA does not increase the toxicity compared to the NA (Manoharan et al., 2018).
To prepare the way for using the isotopically labelled SABRE hyperpolarized 4,6-d₂-nicotinamide as an MRI agent in humans we have performed an in-vivo study to measure its pharmacokinetics in the plasma of healthy rats after intravenous and oral administration. Male Han Wistar rats were dosed with either 4,6-d₂-nicotinamide or the corresponding control, non-labelled nicotinamide, and plasma samples were obtained at eight time points for up to 24 h after administration. Pharmacokinetic parameters were determined from agent concentration-versus-time data for both 4,6-d₂-nicotinamide and nicotinamide. 4,6-d₂-Nicotinamide proved to be well tolerated regardless of route of administration at the concentrations used (20, 80 and 120 mg/kg). Pharmacokinetic parameters were similar after oral and intravenous administration and similar to those obtained for nicotinamide. Analysis of nicotinamide plasma concentrations after dosing 4,6-d₂-nicotinamide intravenously demonstrates a reversible exchange of endogenous nicotinamide by this labelled agent over the time-course of our assays. Supported by a large body of evidence for the safety of nicotinamide when dosed orally in humans, we conclude that 4,6-d₂-nicotinamide can also be safely administered intravenously, which will provide significant benefit when using this agent for planned imaging studies in humans.
Effects of nicotinamide on spatial memory and inflammation after juvenile traumatic brain injury
2019, Behavioural Brain Research
Citation Excerpt :
On sensorimotor tasks, such as, tactile adhesive removal, NAM treated animals’ performances are indistinguishable from sham animals. In addition to improved behavioral outcomes, NAM given at 500 mg/kg reduces the injury lesion size and glial fibrillary acid protein (GFAP) proximal to the injury site [15–18]. Though NAM shows neuroprotection at lower doses in stroke models, efficacy is suggested to be dose- and age-dependent.
Age is a consistent predictor of outcome following traumatic brain injury (TBI). Although children and adolescents have the highest rate of hospitalizations and long-term disabilities, few preclinical studies have attempted to model and treat TBI in this population. Studies using nicotinamide (NAM), a soluble B-group vitamin, in older animals (3–6 months) have shown improved functional recovery in experimental models of TBI. The purpose of this study was two-fold: to examine the preclinical efficacy of NAM at different doses on behavioral outcomes in juvenile rats and examine the microglial response over time. Groups of juvenile rats (PND 28–60) were assigned to sham, NAM (125 mg/kg, 500 mg/kg, or 1000 mg/kg) or saline (1 mL/kg) and received unilateral cortical contusion injuries (CCI) and received injections at 15 min, 24 h, and 72 h after injury. Animals treated with NAM demonstrated no significant behavioral improvements over saline treatments. NAM treatments did however show slowed cortical loss and reduced microglia compared to saline treated animals. In summary, the preclinical efficacy of NAM as a treatment following CCI in juvenile animals differs from that previously documented in older rat models. While NAM treatments did reduce microglial activity and slowed progression of cortical loss, it did not reduce the total cortical volume lost nor did it improve behavioral outcomes. The findings of this study emphasize the need to examine potential treatments for TBI utilizing juvenile populations and may explain why so many treatments have failed in clinical trials.
Pharmacological Nicotinamide: Mechanisms Centered Around SIRT1 Activity
2019, Pharmacoepigenetics
Nicotinamide (NAM) is a dietary source of nicotinamide adenine dinucleotide (NAD⁺). Gram doses of NAM have long been used to treat diverse disease conditions, such as inflammatory diseases and dementia, in humans and animal models. Recent studies have elucidated some of the mechanisms underlying the therapeutic effectiveness of NAM; these appear to be predominantly mediated by its conversion to NAD⁺. By increasing the amount of NAD⁺ and the NAD⁺/NADH ratio, NAM administration alters mitochondrial physiology and ROS generation. It also modulates the activity of many proteins. For example, SIRT1 activation plays important roles by exerting cytoprotection, antiinflammation, and antimetabolic syndrome effects. However, SIRT1 activity in cells can be either positively or negatively regulated by NAM treatment depending on various conditions. In this chapter current understandings of the biochemistry and function of NAM and NAD⁺ are presented with the aim of promoting wider and safer applications of NAM as a pharmaceutical.
Preconditioning is hormesis part I: Documentation, dose-response features and mechanistic foundations
2016, Pharmacological Research
This article provides the first extensive documentation of the dose response features of pre- and postconditioning. Pre- and postconditioning studies with rigorous study designs, using multiple doses/concentrations along with refined dose/concentration spacing strategies, often display hormetic dose/concentration response relationships with considerable generality across biological model, inducing (i.e., conditioning) agent, challenging dose treatment, endpoint, and mechanism. Pre- and postconditioning hormesis dose/concentration-response relationships are reported for 154 diverse conditioning agents, affecting more than 550 dose/concentration responses, across a broad range of biological models and endpoints. The quantitative features of the pre- and postconditioning-induced protective responses are modest, typically being 30–60% greater than control values at maximum, findings that are consistent with a large body (>10,000) of hormetic dose/concentration responses not related to pre- and postconditioning. Regardless of the biological model, inducing agent, endpoint or mechanism, the quantitative features of hormetic dose/concentration responses are similar, suggesting that the magnitude of response is a measure of biological plasticity. This paper also provides the first documentation that hormetic effects account for preconditioning induced early (1–3 h) and delayed (12–72 h) windows of protection. These findings indicate that pre- and postconditioning are specific types of hormesis.

View all citing articles on Scopus

View full text

Post-treatment with nicotinamide (vitamin B3) reduces the infarct volume following permanent focal cerebral ischemia in female Sprague–Dawley and Wistar rats

Abstract

Section snippets

Acknowledgements

Neurosci. Lett.

Radiother. Oncol.

Brain Res.

Brain Res.

Gender-linked brain injury in experimental stroke

Stroke

Delayed treatment with nicotinamide improves neurologic outcome and reduces infarction volume in transient focal cerebral ischemia in rats

Soc. Neurosci. Abstr.

Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate

Ann. Neurol.

Thrombolysis in myocardial infarction investigators

Comparison of clinical outcomes for women and men after acute myocardial infarction. Ann. Intern. Med.

Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke

Middle cerebral artery occlusion in the rat by intraluminal suture

Neurological and pathological evaluation of an improved model, Stroke

Post-treatment with nicotinamide (vitamin B₃) reduces the infarct volume following permanent focal cerebral ischemia in female Sprague–Dawley and Wistar rats

Coenzyme Q₁₀ and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate